Overview

Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.

Phase:

PHASE2

Details

Lead Sponsor:

Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Treatments:

pembrolizumab
zanidatamab